Laekna, Inc.
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People's Republic of China, the United States of America, and South Korea. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer,… Read more
Market Cap & Net Worth: Laekna, Inc. (4U4)
Laekna, Inc. (F:4U4) has a market capitalization of $742.42 Million (€723.28 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #11926 globally and #1275 in its home market, demonstrating a 27.56% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Laekna, Inc.'s stock price €1.62 by its total outstanding shares 446466350 (446.47 Million).
Laekna, Inc. Market Cap History: 2026 to 2026
Laekna, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $742.42 Million to $742.42 Million (0.00% CAGR).
Laekna, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Laekna, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4U4 by Market Capitalization
Companies near Laekna, Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Laekna, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Laekna, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Laekna, Inc.'s market cap moved from $742.42 Million to $ 742.42 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €742.42 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Laekna, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $742.42 Million USD |
| MoneyControl | $742.42 Million USD |
| MarketWatch | $742.42 Million USD |
| marketcap.company | $742.42 Million USD |
| Reuters | $742.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.